2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2417

Antibodies To Porphyromonas Gingivalis Peptidylarginine Deiminase In Rheumatoid Arthritis Are Not Directed Against The Autocitrullinated Enzyme
Abstract Number: 454

Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
Abstract Number: 517

Antibody Responses To Oral Bacteria In Patients With Primary Sjögren’s Syndrome and Comparison With Rheumatoid Arthritis and Periodontitis
Abstract Number: 2262

Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Abstract Number: 736

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Abstract Number: 106

Antinuclear Antibodies Positive But No Autoimmune Disease
Abstract Number: 2586

Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations
Abstract Number: 1689

Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
Abstract Number: 854

Aortic Wall Thickness In Patients Without Aortitis: a Computed Tomography-Based Study Of 100 Patients
Abstract Number: 2215

Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis
Abstract Number: 908

Appearance Dissatisfaction, Social Discomfort, and Helplessness In Patients With Systemic Sclerosis
Abstract Number: 2683

Application Of a Multi-Biomarker Disease Activity (Vectra^® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein
Abstract Number: 157

Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 168 Single Nucleotide Polymorphisms In The Optima Study
Abstract Number: 1021

Application Of a Novel Measure Of Socioeconomic Status Using Individual Housing Data In Rheumatology Research
Abstract Number: 1302

Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].